Press release
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
– Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S – – Positive phase 1 sebetralstat data supports KONFIDENT trial
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S –\n\n– Positive phase 1 sebetralstat data supports KONFIDENT trial expansion to Japan –\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented three posters at the Western Society of Allergy, Asthma & Immunology 60th Annual Scientific Session in Kona, HI.\n\nThe first highlighted that KONFIDENT-S (NCT05505916) is a prospective trial to evaluate the effectiveness and safety of sebetralstat, an investigational oral plasma kallikrein inhibitor, for short-term prophylaxis (STP). The second reported phase 1 data evaluated the pharmacokinetic and pharmacodynamic parameters of sebetralstat in Japanese adults. These positive Phase 1 data support the expansion of the KONFIDENT (NCT05259917) phase 3 trial to Japan. Finally, KalVista presented a post hoc analysis of phase 2 trial data demonstrating that sebetralstat provided similar symptom relief, reduction in attack severity, and use of rescue regardless of abdominal or peripheral attack location.\n\n\nTargeted Literature Review to Assess the Studies Supporting Short-term Prophylactic Treatment Options for the Preprocedural Prevention of Attacks in Patients With Hereditary Angioedema: Dr. Marc A. Riedl, Division of Rheumatology, Allergy and Immunology, University of California San Diego, US\n\n\n\nPharmacokinetic, Pharmacodynamic, and Safety Profile of Sebetralstat in Healthy Japanese and White Adults: Results From a Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial: Matthew Iverson, KalVista Pharmaceuticals Inc., Cambridge, MA, USA\n\n\n\nEfficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema: Dr. Paul K. Audhya, KalVista Pharmaceuticals Inc., Cambridge, MA, USA\n\n\nLinks to all posters and presentations can be found on the KalVista website under “Publications”.\n\nAbout KalVista Pharmaceuticals, Inc.\n\nKalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases...